Compare FTCI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | INO |
|---|---|---|
| Founded | 2017 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 100.4M |
| IPO Year | 2021 | 1999 |
| Metric | FTCI | INO |
|---|---|---|
| Price | $5.37 | $1.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $10.80 | $6.75 |
| AVG Volume (30 Days) | 97.6K | ★ 1.5M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | $42,220,086.00 |
| Revenue This Year | $65.44 | $20,156.19 |
| Revenue Next Year | $45.97 | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.51 | 19.37 |
| 52 Week Low | $3.21 | $1.03 |
| 52 Week High | $12.75 | $2.86 |
| Indicator | FTCI | INO |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 51.80 |
| Support Level | $4.20 | $1.03 |
| Resistance Level | $5.38 | $1.24 |
| Average True Range (ATR) | 0.38 | 0.06 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 83.49 | 53.85 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.